Nebula Genomics is among the first blockchain-based companies to reward users for contributing personal data for research.

Luna DNA, Nebula Genomics, and other “bio-brokers” will allow customers to make money by granting access to their genetic and personal information for research purposes.

Researchers at the Rare Genomics Institute look at how families finance the cost of diagnostic exome sequencing.

Two large-scale studies reveal new insights into the genomic characteristics of childhood cancers.

A handful of infants in a neonatal intensive care unit who were diagnosed with rare diseases using whole-genome sequencing had shorter hospital stays and better health outcomes, researchers find.

The first randomized trial to examine whole-genome sequencing in healthy people uncovers disease-causing genetic variants, but the overall benefits to this population are ambiguous.

DNA sequencing reveals that the virus responsible for the recent outbreak in the Americas originated in Brazil in 2014 and circulated undetected for months before the first cases were reported.

Childhood cancer survivors with mutations in certain cancer-risk genes have a higher risk of developing additional neoplasms later in life, according to research presented at the American Association for Cancer Research annual meeting.

With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.